MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors
News Jan 18, 2012
"We are privileged to welcome Jim to our Board of Directors at this exciting time in the Company's development as we focus our efforts on building a commercial infrastructure to support the launch and commercialization of LEVADEX, if approved," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "The depth of Jim's experience in commercializing new pharmaceutical products in specialist markets will provide great value and we look forward to benefitting from his expertise as we advance LEVADEX."
Mr. O'Shea has extensive experience in the healthcare industry, including eight years at Sepracor where he held various roles in operations and commercialization most recently as Vice Chairman and previously as President and Chief Operating Officer. Prior to Sepracor, Mr. O'Shea held several management positions of increasing responsibility in international sales and marketing, including Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc,. Mr. O'Shea has led the commercial launch of over 10 new products in several therapeutic areas, including migraine and pain.
Mr. O'Shea is a graduate of Liverpool Lord Byron University, where he received an honors degree in applied physics from the Institute of Physics.
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE